

LIQ13

Notice of final account prior to dissolution in MVL



Companies House

For further information, please
refer to our guidance at
www.gov.uk/companieshouse

1 Company details

Company number 09470532

Company name in full RENABLE PHARMA LTD

→ Filling in this form

Please complete in typescript or in
bold black capitals.

2 Liquidator's name

Full forename(s) Laura

Surname Waters

3 Liquidator's address

Building name/number PricewaterhouseCoopers LLP

Street 7 More London Riverside

Post town London

County/Region

Postcode SE12RT

Country

4 Liquidator's name ①

Full forename(s) Steven

Surname Sherry

① Other liquidator

Use this section to tell us about
another liquidator.

5 Liquidator's address ②

Building name/number PricewaterhouseCoopers LLP

Street 7 More London Riverside

Post town London

County/Region

Postcode SE12RT

Country

② Other liquidator

Use this section to tell us about
another liquidator.

LIQ13

Notice of final account prior to dissolution in MVL

6 Final account

☒ I have delivered the final account of the winding up to the members in accordance with Section 94(2) and attach a copy.

7 Sign and date

Liquidator's signature

Signature

X



X

Signature date

d

1

d

1

m

1

m

0

y

2

y

0

y

2

y

2

LIQ13

Notice of final account prior to dissolution in MVL



Presenter information

You do not have to give any contact information, but if you do it will help Companies House if there is a query on the form. The contact information you give will be visible to searchers of the public record.

Contact name Lisa O'Connor

Company name PricewaterhouseCoopers LLP

Address No. 1 Spinningfields

Hardman Street

Post town Manchester

County/Region

Postcode M 2 3 E B

Country

DX

Telephone 07808035857



Checklist

We may return forms completed incorrectly or with information missing.

Please make sure you have remembered the following:

- ☐ The company name and number match the information held on the public Register.
- ☐ You have attached the required documents.
- ☐ You have signed the form.



Important information

All information on this form will appear on the public record.



Where to send

You may return this form to any Companies House address, however for expediency we advise you to return it to the address below:

The Registrar of Companies, Companies House,
Crown Way, Cardiff, Wales, CF14 3UZ.
DX 33050 Cardiff.



Further information

For further information please see the guidance notes on the website at www.gov.uk/companieshouse or email enquiries@companieshouse.gov.uk

This form is available in an alternative format. Please visit the forms page on the website at www.gov.uk/companieshouse

RENABLE PHARMA LTD– IN MEMBERS’ VOLUNTARY LIQUIDATION

FINAL ACCOUNT TO MEMBERS PURSUANT TO SECTION 94 OF THE INSOLVENCY ACT 1986 AND RULE 5.10 OF THE INSOLVENCY (ENGLAND AND WALES) RULES 2016 FOR THE PERIOD FROM 31 JANUARY 2022 TO 11 OCTOBER 2022

ISSUED ON: 11 OCTOBER 2022

INTRODUCTION

Renable Pharma Ltd (Entity) entered members’ voluntary liquidation on 31 January 2022. Laura May Waters and Steven Sherry were appointed joint liquidators of the Entity (Liquidators).

This is the Liquidators’ final account of the liquidation and covers the period 31 January 2022 to 11 October 2022. For the purposes of the summary receipts and payments account (at Appendix A), the Liquidators set out what has been received and paid in the period from 31 January 2022 to 11 October 2022 (the Period).

Statutory information relating to the Entity and the Liquidators is at Appendix B.

REPORT ON THE LIQUIDATION

Realisation of assets:

The below table shows the assets listed on the Directors’ Declaration of Solvency as at 31 January 2022, together with a summary of the assets dealt with by the Liquidators during the course of the liquidation.

| Asset | Declaration of Solvency estimated to realise £ | Liquidation assets £ |
|---------------------|---|---------------------------------|
| Intercompany debtor | 1 | 1 |
| Total | 1 | 1 |

During the Period an intercompany debt of £1 due from Repros Therapeutics Inc, was taken under the control of the Liquidators until distribution.

The Liquidators are not aware of any other assets that remain to be realised.

Settlement of liabilities:

The Directors’ Declaration of Solvency showed that the Entity had no liabilities.

In the Period, the Liquidators published a notice in the London Gazette inviting creditors to submit details of claims they may have against the Entity.

The Liquidators have not received any claims in the liquidation.

HM Revenue & Customs (“HMRC”):

Following their appointment, the Liquidators wrote to HMRC to inform them of the liquidation and to request details of any outstanding liabilities. HMRC have confirmed that the Entity has no outstanding tax liabilities and that they have no objection to the liquidation being closed.

Distributions to Members:

On 14 September 2022 an in-specie distribution of £1 (representing approximately £1 per share) was made to the Member of the Entity. The distribution consisted of an inter-group debt together with any other assets held by the Entity.

RENABLE PHARMA LTD– IN MEMBERS’ VOLUNTARY LIQUIDATION

FINAL ACCOUNT TO MEMBERS PURSUANT TO SECTION 94 OF THE INSOLVENCY ACT 1986 AND RULE 5.10 OF THE INSOLVENCY (ENGLAND AND WALES) RULES 2016 FOR THE PERIOD FROM 31 JANUARY 2022 TO 11 OCTOBER 2022

ISSUED ON: 11 OCTOBER 2022

The value attributed to the distribution was based on the value at which the assets was held in the Entity’s books.

LIQUIDATORS’ FEES AND EXPENSES

Basis of remuneration

The basis of the Liquidators’ remuneration has been fixed by reference to the time properly given by them and their staff in dealing with the liquidation, in accordance with a resolution dated 31 January 2022.

Liquidators’ remuneration and expenses

Fees and expenses of the liquidation have been paid to PricewaterhouseCoopers LLP by another group company under a separate contractual arrangement. There is no recourse to the liquidation estate.

The Liquidators have separately provided the Member with the information required in accordance with Statement of Insolvency Practice 7.

Members’ rights regarding the Liquidators’ remuneration and expenses

Any member of the Entity with permission of the court or members of the Entity with at least 5% of the total voting rights of all the members having the right to vote at general meetings of the entity (or permission of the court) are entitled to request further information about our fees and expenses. Such requests need to be made within 21 days of receipt of this report. See Rule 18.9 of the Insolvency (England and Wales) Rules 2016 for further detail.

Any member of the Entity with permission of the court or members of the Entity with at least 10% of the total voting rights of all the members having the right to vote at general meetings of the entity (or permission of the court) are entitled to claim by way of court application that the liquidators’ fees and expenses are excessive. Such applications need to be made within 8 weeks of the receipt of this report. See Rule 18.34 of the Insolvency (England and Wales) Rules 2016 for further detail.

RENABLE PHARMA LTD– IN MEMBERS’ VOLUNTARY LIQUIDATION

**FINAL ACCOUNT TO MEMBERS PURSUANT TO SECTION 94 OF THE INSOLVENCY ACT 1986 AND
RULE 5.10 OF THE INSOLVENCY (ENGLAND AND WALES) RULES 2016 FOR THE PERIOD FROM 31
JANUARY 2022 TO 11 OCTOBER 2022**

ISSUED ON: 11 OCTOBER 2022

APPENDIX A

**ABSTRACT OF RECEIPTS AND PAYMENTS IN THE LIQUIDATION DURING THE PERIOD
FROM 31 JANUARY 2022 TO 11 OCTOBER 2022**

| | From 31 January 2022 To 11 October 2022 | £ |
|----------------------|--|------------|
| RECEIPTS | | |
| Total | <hr/> | NIL |
| PAYMENTS | | |
| Total | <hr/> | NIL |
| DISTRIBUTIONS | | |
| Total | <hr/> | NIL |
| TOTAL BALANCE | <hr/> <hr/> | NIL |

Note:

The Liquidators did not operate a bank account during the course of the Liquidation. As such, there are no cash receipts or payments to report on. Please see the assets, liabilities and distributions sections in the main body of the report for details on how the Liquidators dealt with the Entity’s assets and liabilities.

RENABLE PHARMA LTD– IN MEMBERS’ VOLUNTARY LIQUIDATION

FINAL ACCOUNT TO MEMBERS PURSUANT TO SECTION 94 OF THE INSOLVENCY ACT 1986 AND RULE 5.10 OF THE INSOLVENCY (ENGLAND AND WALES) RULES 2016 FOR THE PERIOD FROM 31 JANUARY 2022 TO 11 OCTOBER 2022

ISSUED ON: 11 OCTOBER 2022

APPENDIX B

INFORMATION ON THE ENTITY AND THE LIQUIDATORS

Entity Details

Entity’s registered name: Renable Pharma Ltd

Entity’s registered number: 09470532

Liquidators’ Details

Liquidators’ names: Laura Waters and Steven Sherry

Liquidators’ postal address: c/o PricewaterhouseCoopers LLP, 7 More London Riverside,
London, SE1 2RT

Liquidators’ email: laura.m.waters@pwc.com
steven.a.sherry@pwc.com

Nature of appointment: Members’ voluntary liquidation

Laura Waters and Steven Sherry were appointed as joint liquidators of the Entity. They are licensed in the United Kingdom to act as insolvency practitioners by the Institute of Chartered Accountants in England and Wales. The joint liquidators are bound by the Insolvency Code of Ethics which can be found at: <https://www.gov.uk/government/publications/insolvency-practitioner-code-of-ethics>.

The Liquidators may act as controllers of personal data as defined by UK data protection law depending upon the specific processing activities undertaken. PricewaterhouseCoopers LLP may act as a processor on the instructions of the Liquidators. Personal data will be kept secure and processed only for matters relating to the liquidation. Further details are available in the privacy statement on the PwC.co.uk website or by contacting the Liquidators.